Evaluations of the Chuanqi Ophthalmic Microemulsion In Situ Gel on Dry Age-Related Macular Degeneration Treatment

Abstract EN

Age-related macular degeneration (AMD) is the third largest eye disease.

However, the eye has a variety of drug delivery barriers, which prevent the drug from reaching the lesions in the posterior segment of the eye, coupled with the pathogenesis of dry-AMD; these lead to the lack of effective treatment drugs for dry-AMD.

Therefore, the developments of a suitable therapeutic drug and a novel ophthalmic preparation are of great significance for the treatment of dry-AMD.

The purposes of this study were to construct a novel traditional Chinese medicine (Chuanqi Fang) anti-AMD microemulsion in situ gel for treating dry-AMD and investigate its characteristic, efficiency, irritation, and tissue distribution.

In this study, the characteristic of the Chuanqi microemulsion in situ gel was measured by dynamic light scattering.

The electroretinogram (ERG) indicators and the number of retinal pigment epithelial cells were measured to evaluate the therapeutic effect of the novel ophthalmic nanopreparations.

Irritation was evaluated according to Technical Guideline Principles (ZGPT4-1).

The analysis of tissue distribution was carried out with LC-MS.

The research showed that the particle size of microemulsion was 38.56 ± 0.21 nm.

The Chuanqi microemulsion in situ gel had certain roles in repairing retina damage of the dry-AMD animal model and showed no irritation.

The tissue distribution study found that the microemulsion in situ gel could effectively deliver the drug to the posterior eye of the AMD model rat through the route of cornea-vitreous body-retina.

In conclusion, this study provided a meaningful research strategy and research basis for the development of new dry-AMD therapeutic drugs.